Pacira BioSciences, Inc. (NASDAQ:PCRX) Insider Jonathan Slonin Sells 879 Shares

Pacira BioSciences, Inc. (NASDAQ:PCRX) insider Jonathan Slonin sold 879 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $18.40, for a total value of $16,173.60. Following the sale, the insider now owns 93,444 shares of the company’s stock, valued at approximately $1,719,369.60. This represents a 0.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Pacira BioSciences Trading Up 1.3 %

NASDAQ PCRX opened at $18.63 on Tuesday. Pacira BioSciences, Inc. has a 12-month low of $11.16 and a 12-month high of $35.95. The company has a fifty day simple moving average of $18.06 and a two-hundred day simple moving average of $17.92. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The stock has a market cap of $860.20 million, a P/E ratio of -9.18 and a beta of 0.76.

Hedge Funds Weigh In On Pacira BioSciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PCRX. Quest Partners LLC acquired a new position in shares of Pacira BioSciences in the second quarter valued at about $113,000. Canada Pension Plan Investment Board purchased a new stake in Pacira BioSciences in the second quarter valued at approximately $140,000. Virtus Investment Advisers Inc. acquired a new position in Pacira BioSciences in the 3rd quarter worth approximately $98,000. CWM LLC raised its position in Pacira BioSciences by 713.6% during the 3rd quarter. CWM LLC now owns 6,517 shares of the company’s stock worth $98,000 after buying an additional 5,716 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in Pacira BioSciences by 62.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company’s stock worth $134,000 after buying an additional 3,404 shares during the last quarter. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on PCRX shares. Barclays decreased their price objective on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Pacira BioSciences in a report on Friday, November 8th. HC Wainwright restated a “buy” rating and issued a $39.00 price target on shares of Pacira BioSciences in a report on Wednesday, December 4th. Royal Bank of Canada boosted their price objective on shares of Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 7th. Finally, Jefferies Financial Group increased their target price on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Pacira BioSciences has an average rating of “Hold” and a consensus target price of $23.50.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.